Quick Answer
Barinthus Biotherapeutics plc. reported Operating Income Loss of -$70.56 million for the year ending 2025.
- Barinthus Biotherapeutics plc. showed a decrease of -3.8% in Operating Income Loss from 2024 to 2025.
- This data is from Barinthus Biotherapeutics plc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Barinthus Biotherapeutics plc.'s Operating Income Loss has declined by 252.0%.
- Historical annual values: Fiscal year 2025: -$70.56 million | Fiscal year 2024: -$67.97 million | Fiscal year 2023: -$83.91 million | Fiscal year 2022: -$4.04 million | Fiscal year 2021: -$45.22 million | Fiscal year 2020: -$20.05 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: